Literature DB >> 8155394

What is the place of carboplatin in paediatric oncology?

F Doz1, R Pinkerton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8155394     DOI： 10.1016/0959-8049(94)90086-8

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  9 in total

Review 1.  Clinical pharmacokinetics and dose optimisation of carboplatin.

Authors:  S B Duffull; B A Robinson
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

2.  Antineoplastic drug, carboplatin, protects mice against visceral leishmaniasis.

Authors:  Tejinder Kaur; Prerna Makkar; Kulbir Randhawa; Sukhbir Kaur
Journal:  Parasitol Res       Date:  2012-09-09       Impact factor: 2.289

3.  Role of chemotherapy alone or in combination with hyperthermia in the primary treatment of intraocular retinoblastoma: preliminary results.

Authors:  C Levy; F Doz; E Quintana; H Pacquement; J Michon; P Schlienger; P Validire; B Asselain; L Desjardins; J M Zucker
Journal:  Br J Ophthalmol       Date:  1998-10       Impact factor: 4.638

4.  Novel retinoblastoma treatment avoids chemotherapy: the effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LH(BETA)T(AG) retinoblastoma tumors.

Authors:  Samuel K Houston; Yolanda Piña; Timothy G Murray; Hinda Boutrid; Colleen Cebulla; Amy C Schefler; Wei Shi; Magda Celdran; William Feuer; Jaime Merchan; Ted J Lampidis
Journal:  Clin Ophthalmol       Date:  2011-01-27

5.  Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer.

Authors:  Esmee Cm Kooijmans; Arend Bökenkamp; Nic S Tjahjadi; Jesse M Tettero; Eline van Dulmen-den Broeder; Helena Jh van der Pal; Margreet A Veening
Journal:  Cochrane Database Syst Rev       Date:  2019-03-11

6.  Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.

Authors:  B Peng; M J Tilby; M W English; L Price; A D Pearson; A V Boddy; D R Newell
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Dose-related nephrotoxicity of carboplatin in children.

Authors:  M W English; R Skinner; A D Pearson; L Price; R Wyllie; A W Craft
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

Review 8.  SIOP PNET5 MB Trial: History and Concept of a Molecularly Stratified Clinical Trial of Risk-Adapted Therapies for Standard-Risk Medulloblastoma.

Authors:  Martin Mynarek; Till Milde; Laetitia Padovani; Geert O Janssens; Robert Kwiecien; Veronique Mosseri; Steven C Clifford; François Doz; Stefan Rutkowski
Journal:  Cancers (Basel)       Date:  2021-12-02       Impact factor: 6.639

9.  Carboplatin Dosing in Children Using Estimated Glomerular Filtration Rate: Equation Matters.

Authors:  Mirjam E van de Velde; Emil den Bakker; Hester N Blufpand; Gertjan L Kaspers; Floor C H Abbink; Arjenne W A Kors; Abraham J Wilhelm; Richard J Honeywell; Godefridus J Peters; Birgit Stoffel-Wagner; Laurien M Buffart; Arend Bökenkamp
Journal:  Cancers (Basel)       Date:  2021-11-26       Impact factor: 6.639
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.